Drug Uses

Gris-PEG is prescribed for the treatment of the following ringworm infections: Athlete's foot, Barber's itch (inflammation of the facial hair follicles), Ringworm of the body, Ringworm of the groin and thigh, Ringworm of the nails, Ringworm of the scalp. Because Gris-PEG is effective only for certain types of fungal infections, before treatment your doctor may perform tests to identify the source of infection.

How Taken

Accurate diagnosis of the infecting organism is essential. Adults: Daily administration of 330 mg (as a single dose or in divided amounts) will give a satisfactory response. Children: Approximately 3.3 mg per pound of body weight per day is an effective dose for most children.

Warnings/Precautions

Because Gris-PEG can make you sensitive to light, avoid exposure to intense natural or artificial sunlight. Notify your doctor if you develop lupus erythematosus (a form of rheumatism) or a lupus-like condition. Signs and symptoms of lupus include arthritis, red butterfly rash over the nose and cheeks, tiredness, weakness, sensitivity to sunlight, and skin eruptions. If you are being treated with Gris-PEG for an extended period of time, your doctor should perform regular tests, including periodic monitoring of kidney function, liver function, and blood cell production. Gris-PEG has not been proved safe and effective for the prevention of fungal infections. Gris-PEG may decrease the effectiveness of birth-control pills. Use additional protection while you are taking Gris-PEG. Men should wait at least 6 months after finishing therapy with Gris-PEG before they father a child. Women should avoid becoming pregnant while they are taking the drug.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the one you missed and go back to your regular schedule. Do not take 2 doses at once.

Possible Side Effects

When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria, erythema multiform-like drug reactions, and rarely, angioneurotic edema, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesias of the hands and feet have been reported rarely after extended therapy. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastria distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion, and impairment of performance of routine activities. Administration of the drug should be discontinued if granulocytopenia occur. When rare, serious reactions occur with Gris-PEG, they are usually associated with high dosages, long periods of therapy, or both.

Storage

Store Gris-PEG tablets at controlled room temperature 15°-30°C (59°-86°F) in tight, light-resistant containers.

Overdose

Any medication taken in excess can have dangerous consequences. If you suspect an overdose of Gris-PEG, seek emergency medical treatment immediately.

More Information

Gris-PEG may intensify the effects of alcohol. If you drink alcohol while taking this medication, your heart may start beating faster and your skin may be flushed. If Gris-PEG is taken with certain other drugs, the effects could be increased, decreased, or altered. It is especially important to check with your doctor before combining Gris-PEG with the following: Blood-thinning drugs such as Coumadin, Barbiturates such as Phenobarbital, Oral Contraceptives.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Gris-peg at Wikipedia.org and other resources:

Microencapsulation of Islets with Living Cells Using PolyDNA-PEG-Lipid Conjugate
Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Bioconjugate Chemistry)

Multilayer Buildup and Biofouling Characteristics of PSS-b-PEG Containing Films
Langmuir, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Langmuir)

Acceleration of the gastrointestinal transit by polyethylene glycol effectively treats unconjugated hyperbilirubinaemia in Gunn rats
Conclusion Gastrointestinal transit time and plasma UCB concentrations are linearly related in Gunn rats. This relationship can be exploited by pharmacologically accelerating the gastrointestinal transit, which increases transmucosal UCB diffusion and thereby effectively treats unconjugated hyperbilirubinaemia. Present results support the feasibility of PEG treatment, either solitary or combined with phototherapy, in patients with severe unconjugated hyperbilirubinaemia. (Source: Gut)

Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome.
Conclusions: The UGT1A1*28 genotype and male gender predict an increased incidence of LFT abnormalities during PEG therapy in acromegaly. PMID: 20207827 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

In Situ Growth of Side-Chain PEG Polymers from Functionalized Human Growth Hormone—A New Technique for Preparation of Enhanced Protein−Polymer Conjugates
Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Bioconjugate Chemistry)